December 2022 in “Pakistan Journal of Medical and Health Sciences” Tofacitinib effectively treats Alopecia Areata.
July 2024 in “Journal of Investigative Dermatology” IL-13 protein is much higher in the skin of atopic dermatitis patients than in healthy skin.
3 citations
,
November 2017 in “PubMed” Alopecia areata progression is linked to stress and hormone changes, suggesting new treatment targets.
April 2025 in “Pakistan Journal of Health Sciences” Weekly Azathioprine Pulse therapy is more effective than Betamethasone Oral Mini-Pulse for hair regrowth in moderate to severe Alopecia Areata.
4 citations
,
June 2025 in “Frontiers in Immunology” BAFF-targeted therapies can reduce autoimmune disease activity, but more research is needed for precise treatments.
6 citations
,
January 2017 in “Dermato-endocrinology” ADT-G may be a useful indicator of increased androgen levels in women with acne and can be lowered with certain birth control pills.
January 2026 in “Journal of the Egyptian Womenʼs Dermatologic Society” High levels of HSP70 and IL-15 are linked to more severe alopecia areata.
11 citations
,
September 2021 in “Anais Brasileiros de Dermatologia” The conclusion is that early diagnosis of skin signs linked to diseases like Lupus, Dermatomyositis, and Rheumatoid Arthritis is crucial to prevent serious complications.
37 citations
,
June 2018 in “Clinical and Experimental Medicine” People with alopecia areata often have lower vitamin D levels and more inflammation, suggesting vitamin D might be involved in the condition.
July 2024 in “Indonesian Journal of Case Reports” Effective treatment improved skin and overall symptoms in a lupus patient.
5 citations
,
April 2019 in “Journal of Nepal Health Research Council” People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.
17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
June 2024 in “JEADV Clinical Practice” Severe alopecia areata patients have a low chance of spontaneous hair regrowth.
2 citations
,
September 2023 in “Journal of the Egyptian Womenʼs Dermatologic Society” Exclamation mark hairs and broken hairs best indicate active alopecia areata.
6 citations
,
February 2016 in “British Journal of Dermatology” A woman with a drug allergy to anakinra was successfully desensitized, allowing her to continue treatment without allergic reactions.
February 2018 in “Chin J Clinicians(Electronic Edition)” Rash in SLE patients indicates more severe disease.
130 citations
,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
October 2024 in “International Journal of Research in Dermatology” Tofacitinib is a promising and safe treatment for moderate to severe alopecia areata.
Baricitinib is more effective than tofacitinib for hair regrowth in alopecia patients.
December 2023 in “European journal of dermatology/EJD. European journal of dermatology” More effective treatments are needed for severe alopecia areata.
1 citations
,
January 2021 in “Arthritis Research & Therapy” About 8% of people with systemic lupus erythematosus have chronic scarring alopecia, with certain symptoms and positive antibodies increasing the risk, while immunosuppressants may lower it.
2 citations
,
February 2014 in “Journal of Crohn's and colitis” Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.
3 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Dermatologists are hesitant to prescribe Janus kinase inhibitors for alopecia areata due to safety concerns and lack of knowledge.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.
1 citations
,
September 2022 in “JMIR dermatology” Alopecia Areata greatly affects the quality of life and mental health of Canadian patients and their caregivers.
13 citations
,
April 2021 in “Value in Health” There is a significant need for better-validated quality of life tools in dermatology.
1 citations
,
January 2025 in “Annals of Dermatology” Baricitinib is effective and safe for treating alopecia areata in Korea.
9 citations
,
January 2013 in “Indian journal of dermatology, venereology, and leprology” Infliximab may cause hair loss in Crohn's disease patients.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.